STOCK TITAN
  1. Home
  2. News
  3. RVMD

Revolution Medicines Inc - RVMD STOCK NEWS

Welcome to our dedicated news page for Revolution Medicines (Ticker: RVMD), a resource for investors and traders seeking the latest updates and insights on Revolution Medicines.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Revolution Medicines's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Revolution Medicines's position in the market.

News
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
Rhea-AI Summary
Revolution Medicines, Inc. announces the publication of a peer-reviewed research paper detailing the discovery and translation of RMC-6236, an investigational RAS(ON) multi-selective inhibitor, with promising preclinical data and case studies. The paper highlights the potential of RMC-6236 in inhibiting RAS-dependent tumor growth across multiple cancer types, achieving deep and durable tumor regressions. Case studies from the Phase 1/1b clinical trial show complete responses in patients with NSCLC and PDAC, supporting the anti-tumor activity of RMC-6236.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.38%
Tags
none
-
News
Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
Rhea-AI Summary
Revolution Medicines, Inc. (RVMD) announces groundbreaking research on RMC-7977, a RAS(ON) multi-selective tri-complex inhibitor with potent anti-tumor activity in RAS-mutant pancreatic cancer. The two Nature papers highlight the discovery, translational implications, and broad-spectrum potential of RMC-7977 in targeting various RAS mutations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.33%
Tags
none
-
News
Revolution Medicines to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Revolution Medicines, Inc. (RVMD) CEO to speak at healthcare conferences. Mark A. Goldsmith, M.D., Ph.D., will be featured at the 23rd Annual Needham Healthcare Conference and the Stifel Targeted Oncology Forum. Webcasts available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
conferences
News
Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024
Rhea-AI Summary
Revolution Medicines, Inc. (RVMD) will present multiple groundbreaking discoveries at the AACR Annual Meeting 2024, focusing on innovative therapies for RAS-addicted cancers. Key presentations include new RAS inhibitors, combination therapies, and potential biomarkers. The company aims to address drug resistance and enhance treatment outcomes for cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
conferences
-
News
Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate Progress
Rhea-AI Summary
Revolution Medicines, Inc. (RVMD) announced financial results for Q4 and full year 2023, focusing on RAS(ON) inhibitors development. The company aims to advance RMC-6236 into pivotal trials for NSCLC and PDAC, expand its reach into earlier therapy lines and qualify mutant-selective inhibitors. With a year-end cash balance of $1.85 billion after acquiring EQRx, Revolution Medicines is well-positioned for future developments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
earnings
-
News
Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024
Rhea-AI Summary
Revolution Medicines, Inc. (RVMD) will report financial results for Q4 and full year 2023 on Feb 26, 2024. The company is a clinical-stage oncology firm focusing on RAS-addicted cancers. A webcast by senior management will discuss financial results and corporate progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
News
Revolution Medicines to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Revolution Medicines, Inc. CEO Mark A. Goldsmith, M.D., Ph.D. will be a featured speaker at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference and the TD Cowen 44th Annual Health Care Conference. The company's participation details, including dates, times, and locations, are provided in the press release. Live webcasts and replays of the presentations will be available on the Revolution Medicines website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.71%
Tags
conferences
-
News
Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Revolution Medicines, Inc. (RVMD) announced that their CEO will deliver a corporate presentation at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024, to discuss the development of targeted therapies for RAS-addicted cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.14%
Tags
conferences
-
News
Revolution Medicines Completes Acquisition of EQRx
Rhea-AI Summary
Revolution Medicines, Inc. (Nasdaq: RVMD) announced the completion of its acquisition of EQRx, Inc., adding approximately $1.1 billion in net cash to its balance sheet. This move supports the late-stage development of RAS(ON) Inhibitor investigational drugs. Dr. Sandra Horning, a seasoned oncologist and late-stage clinical development leader, has joined Revolution Medicines' Board of Directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.48%
Tags
acquisition
News
Revolution Medicines and EQRx Stockholders Approve EQRx Acquisition
Rhea-AI Summary
RVMD and EQRX Stockholders Approve Acquisition Deal, Expected to Close in November 2023. Revolution Medicines to Issue 55 Million Shares for the Merger.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.44%
Tags
acquisition
Stock RVMD logo
Revolution Medicines Inc

Nasdaq:RVMD

RVMD Rankings

#1092 Ranked by Market Cap
#2552 Ranked by Stock Gains
N/A Ranked by Dividends

RVMD Stock Data

5.94B
160.83M
2.46%
96.16%
7.29%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Redwood City

About RVMD

revolution medicines discovers and develops new drugs that harness the therapeutic potential of frontier oncology targets on behalf of cancer patients. our innovative product engine draws inspiration from nature and evolution, which offer insights into cancer targets, disease mechanisms and therapeutic approaches. we pay particular attention to natural products that are inherently rich with biological function as a result of natural selection and can inform and guide our discovery and development of small molecules that can modulate these targets.